GlassScriptPhysician profile
Anna Rickman Rooks
NPI 1497583975
$1,381.60
in general payments reported to CMS, 2019-2025
28 companies · $859 in 2025
The $859 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $523 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $290.81 | 2024-2025 | Carto 3 |
| Beone Medicines USA, INC. | $108.36 | 2025 | Tevimbra, Brukinsa |
| Astrazeneca Pharmaceuticals LP | $92.00 | 2025 | Calquence, Imfinzi |
| Janssen Biotech, INC. | $82.26 | 2024-2025 | Rybrevant, Akeega, Balversa |
| E.R. Squibb & Sons, L.L.C. | $66.30 | 2024-2025 | Opdivo, Krazati, Opdualag |
| Novartis Pharmaceuticals Corporation | $63.89 | 2024-2025 | |
| Incyte Corporation | $61.42 | 2024-2025 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $53.65 | 2024-2025 | Ninlaro, Fruzaqla |
| Lilly USA, LLC | $49.10 | 2024-2025 | Verzenio, Jaypirca |
| Stemline Therapeutics INC. | $48.14 | 2025 | Orserdu |
| Celgene Corporation | $43.71 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $41.52 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Exelixis INC. | $41.06 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $31.44 | 2024 | Enhertu |
| Abbvie INC. | $30.25 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.34 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2025 | |
| Astellas Pharma US INC | $27.39 | 2025 | Xtandi |
| Alexion Pharmaceuticals, INC. | $24.28 | 2025 | Ultomiris |
| Eisai INC. | $21.99 | 2024 | |
| Array Biopharma INC | $20.94 | 2025 | Braftovi, Mektovi, Tukysa |
| Aveo Pharmaceuticals, INC. | $19.73 | 2024 | |
| Pfizer INC. | $18.56 | 2025 | |
| Sumitomo Pharma America, INC. | $18.41 | 2024 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $17.58 | 2024 | Qinlock |
| Regeneron Healthcare Solutions, INC. | $17.53 | 2024 | Libtayo |
| Genmab U.S., INC. | $17.50 | 2025 | Epkinly |
| Genzyme Corporation | $16.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Rooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.